Company
RayzeBio
Discovering and developing radiopharmaceuticals for patients living with cancer
Also known as RayzeBio, Inc.
- Status
- Acquiredas of 2026-09-18Source (opens in a new tab)
- Business model
- B2B
- Legal name
- RayzeBio, Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
We are focused on creating precision radiopharmaceutical therapies (RPTs) that transform people’s lives. With an innovation-leading position in actinium-based RPTs and a pipeline of potentially first-in-class and best-in-class drug development programs, we are at the forefront of pioneering the application of the next wave in cancer treatment.
Funding snapshot
- Total raised
- $396MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $168M2022-08-25
Funding rounds
- Round, 2022
- $168M2022-08-25, SEC form D sold, 18 investors
- Round, 2021
- $109M2021-06-08, SEC form D sold, 23 investors
- Round, 2020
- $105M2020-11-23, SEC form D sold, 17 investors
- Round, 2020
- $15M2020-08-05, SEC form D sold, 9 investors
About the company
- Status notes
- RayzeBio, a Bristol Myers Squibb Company
Loading relationship preview